U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000005: Diary of Irritable Bowel Syndrome Symptoms- Constipation/ Diarrhea/ Mixed (DIBSS-C/D/M)
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000005: Diary of Irritable Bowel Syndrome Symptoms- Constipation/ Diarrhea/ Mixed (DIBSS-C/D/M)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Immunology and Inflammation (OII)
Division of Gastroenterology (DG)

DDT COA Number
DDT COA #000005

Instrument Name
Diary of Irritable Bowel Syndrome Symptoms- Constipation/ Diarrhea/ Mixed (DIBSS-C/D/M)

Disease/Condition
Irritable Bowel Syndrome (IBS)

Concept of Interest
IBS signs and symptoms

Context of Use
Adult patients with IBS-C, IBS-D, or IBS-M

COA Type
PRO

Qualification Stage
In transition to 507 process 

Requestor(s)
Critical Path Institute: Patient-Reported Outcome (PRO) Consortium
Irritable Bowel Syndrome (IBS) Working Group

Contact(s)
Stephen Coons

Date Accepted into CDER’s COA Qualification Program
April 29, 2010

Back to Top